These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1756325)

  • 1. Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features.
    Baro J; Richard C; Calavia J; González-San Miguel JD; Bello-Fernández C; Alsar MJ; Gómez-Casares MT; Iriondo A; Conde E; Hermosa V
    Bone Marrow Transplant; 1991 Oct; 8(4):283-9. PubMed ID: 1756325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.
    de Kreuk M; Ossenkoppele GJ; Meijer CJ; Huijgens PC
    Bone Marrow Transplant; 1996 Jun; 17(6):963-71. PubMed ID: 8807101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO.
    Conde E; Sierra J; Iriondo A; Domingo A; García Laraña J; Marín J; Caballero D; Martínez F; León A; García-Conde J
    Bone Marrow Transplant; 1994 Aug; 14(2):279-86. PubMed ID: 7994243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
    Da WM; Zhong JT; Liu Y; Huang YS; Bai H; Wu XX; Ou YX; Wang CB; Xu SF
    Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
    Caracciolo D; Gavarotti P; Aglietta M; Bondesan P; Falda M; Gallo E; Locatelli F; Novarino A; Paolino F; Sanavio F
    Bone Marrow Transplant; 1993 Dec; 12(6):621-5. PubMed ID: 7907906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma.
    Cervantes F; Shu XO; McGlave PB; Ramsay NK; Miller WJ; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1995 Sep; 16(3):387-92. PubMed ID: 8535311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
    Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
    Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Kessinger A; Nademanee A; Forman SJ; Armitage JO
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):577-87. PubMed ID: 1972701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
    Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
    Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma].
    Shi Y; Lei Y; Zhou S
    Zhonghua Yi Xue Za Zhi; 1998 Sep; 78(9):658-61. PubMed ID: 11038787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
    Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point.
    Bolwell B; Goormastic M; Andresen S
    Bone Marrow Transplant; 1997 Mar; 19(5):443-8. PubMed ID: 9052909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.